moroctocog alfa (AF-CC)

BIOLOGICAL2 trials

Sponsors

Pfizer

Conditions

Hemophilia A

Phase 1

Relative Bioavailability Of Two Formulations Of Moroctocog Alfa (AF-CC)

CompletedNCT01579903

PfizerHemophilia A

Start: 2012-08-31End: 2013-01-31Updated: 2013-02-08

Phase 3

Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII

CompletedNCT00543439

PfizerHemophilia A

Start: 2007-12-31End: 2018-04-30Updated: 2019-01-11